Loading
Edwards Lifesciences Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Nov 2021.
Edwards Lifesciences Corp: what insiders have been doing
Headquartered in Irvine, United States, Edwards Lifesciences Corp belongs to the Healthcare & Pharma sector and traces its origins to 1956. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 76 filings signed by 17 insiders.
There is no open-market purchase to report; the filings show 25 sales worth €10.8M by 9 insiders. The totals exclude 1 filing filed without an amount. One trade stands out by size: a sale of €2.4M from Chopra Daveen, disclosed on 26 August 2026, or 0.0054% of market capitalisation.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 76 filings, this issuer sits above that mark. Since 2016, the database holds 1 purchase and 59 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 6.07 bn USD and net income at 1.07 bn USD.
Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
518
Thresholds
n/a
Buy Volume
€149,708
1 ops. · all time
Sell Volume
€20M
59 ops. · all time
Who traded when
BuySaleDaveen Chopra7 sales
Bobo Donald e Jr6 sales
Daniel J. Lippis6 sales
Wayne Markowitz6 sales
Andrew M. Dahl2 sales
Ullem Scott B.2 sales
+4 other insiders
Since the insiders bought
- -30.3%Entry US$109.52 · Close at T+365 US$76.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Edwards Lifesciences Corp Buy (bullish), based on 26 analysts. Average price target: US$101.96.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,501 of 24,158 companies
56.9
score / 100
Value36
Quality78
FCF yld2.7%
Earn yld2.2%
EV/EBITDA34.9x
ROE9.2%
Gross mgn78%
Net mgn18%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$86.45
Analyst consensus
26 analystsBuy
US$84.00Target US$101.96(+18%)US$110.00
Income statement
RevenueUS$6.1B
Gross profitUS$4.7B78% margin
EBITDAUS$1.4B24% margin
Net incomeUS$1.1B15.4% margin
Valuation
PER (trailing)51.5x
PER (forward)25.6x
P/Book4.7x
Beta0.86
Balance sheet & cash
Market capUS$49.8B
Total debtUS$705.4M
Free Cash FlowUS$1.3B
Debt / Equity7%
Profitability & ownership
ROE9.2%
ROA8.4%
% insiders0.2%
% institutions95.6%
Last declaration on 8 October 2026
Declarations518 total
619 shares@ US$72.680.0001% mcap2.5% of flowCommon StockSEC:0001225208-26-008338:0
619 shares@ US$85.650.0001% mcap3.0% of flowCommon StockSEC:0001225208-26-008338:1
253 shares@ US$84.370.0000% mcap9.8% of flowCommon StockSEC:0001225208-26-007811:0
355 shares@ US$86.770.0001% mcap1.1% of flowCommon StockSEC:0001225208-26-007812:0
568 shares@ US$84.370.0001% mcap1.7% of flowCommon StockSEC:0001225208-26-007812:1
619 shares@ US$72.680.0001% mcap2.6% of flowCommon StockSEC:0001225208-26-007774:0
398 shares@ US$86.770.0001% mcap0.2% of flowCommon StockSEC:0001225208-26-007775:0
619 shares@ US$87.510.0001% mcap3.1% of flowCommon StockSEC:0001225208-26-007774:1
544 shares@ US$91.05510.0001% mcap22.8% of flowCommonSEC144:0001921094-26-000970
544 shares@ US$91.0550.0001% mcap22.8% of flowCommon StockSEC:0001225208-26-007408:0
2,644 shares@ US$89.980.0005% mcap48.1% of flowCommonSEC144:0001921094-26-000963
2,644 shares@ US$89.980.0005% mcap48.1% of flowCommon StockSEC:0001225208-26-007377:0
31,800 shares@ US$91.02010.0056% mcap20.1% of flowCommonSEC144:0001921094-26-000958
1,240 shares@ US$91.46530.0002% mcap3.9% of flowCommonSEC144:0001921094-26-000959
31,800 shares@ US$72.680.0045% mcap16.0% of flowCommon StockSEC:0001225208-26-007335:0
1,154 shares@ US$91.76140.0002% mcap0.7% of flowCommon StockSEC:0001225208-26-007335:1
30,646 shares@ US$90.99220.0054% mcap19.3% of flowCommon StockSEC:0001225208-26-007335:2
1,240 shares@ US$91.4650.0002% mcap3.9% of flowCommon StockSEC:0001225208-26-007332:0
1,857 shares@ US$92.03020.0003% mcap9.9% of flowCommonSEC144:0001921094-26-000827
619 shares@ US$72.680.0001% mcap2.6% of flowCommon StockSEC:0001225208-26-007065:0
619 shares@ US$92.030.0001% mcap3.3% of flowCommon StockSEC:0001225208-26-007065:1
50,000 shares@ US$92.500.0092% mcap25.4% of flowCommonSEC144:0001921094-26-000777
147 shares@ US$85.63270.0000% mcap0.4% of flowCommonSEC144:0001921094-26-000776
146.313 shares@ US$86.03380.0000% mcap0.4% of flowCommon StockSEC:0001225208-26-006853:0
9,628 shares@ US$85.060.0016% mcap28.9% of flowCommonSEC144:0001921094-26-000762
25 of 518 declarations
About Edwards Lifesciences Corp
Edwards Lifesciences Corp. (ticker: EW) is a leading U.S. medical technology company listed on the NYSE in the United States. For French-speaking investors, it stands out as a highly focused cardiovascular medtech platform, with a business model centered primarily on structural heart disease. The company’s roots date back to 1958, when Miles “Lowell” Edwards set out to develop the first artificial heart. The modern company emerged from Edwards Laboratories and later became an independent public company in 2000 following its spin-off from Baxter International. Edwards is headquartered in Irvine, California, which remains an important part of its innovation and engineering identity.
The company’s core business is organized around three major pillars. The first is transcatheter aortic valve replacement, or TAVR/TAVI, anchored by the SAPIEN franchise, which has become one of the most established names in aortic valve therapy worldwide. The second is transcatheter mitral and tricuspid therapies, or TMTT, a younger but strategically critical growth area as Edwards extends its reach beyond the aortic valve into more complex structural heart procedures. The third pillar is surgical structural heart, which includes tissue heart valves and related products used in complex cardiac surgery. This concentrated portfolio gives Edwards a strong clinical identity and positions the company as a specialized innovator rather than a broad-based medtech conglomerate.
Read moreShow less
From a competitive standpoint, Edwards is widely regarded as a global leader in several structural heart categories, but it operates in a field with serious rivals, including Medtronic and Abbott. Its moat is based on clinical evidence, physician relationships, product innovation, and the breadth of its valve technology platform. The company distributes its products internationally and serves clinicians in nearly 100 countries, giving it meaningful geographic diversification even though the United States remains a key revenue and development market.
Recent news has reinforced the investment case. In late 2025, Edwards received FDA approval for SAPIEN M3, which it described as the first transseptal transcatheter therapy approved in the U.S. for mitral regurgitation. In early 2026, management reported strong full-year 2025 results, highlighted double-digit sales growth, and increased confidence in the 2026 outlook. The company has also been active on capital allocation, including share repurchases, and announced a CFO appointment in May 2026. Overall, EW is best viewed as a premium U.S. healthcare growth stock on the NYSE, supported by a deep structural heart franchise, a strong innovation pipeline, and continued expansion into adjacent valve therapies.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
